Search results
Results from the WOW.Com Content Network
Lupin's businesses encompass the entire pharmaceutical value chain, ranging from branded and generic formulations, APIs, advanced drug delivery systems to biotechnology. . The company's drugs reach 70 countries [22] with a footprint that covers advanced markets such as USA, Europe, Japan, [23] Australia as well as emerging markets including India, the Philippines and South Africa to name a
Gupta joined Lupin in 1993, [3] and became CEO in 2013. Gupta was the chairman and CEO of Lupin Pharmaceuticals Inc, from 2003 to 2013, and grew the US business from 5% to over 45% of Lupin's total turnover. [2] The US is Lupin's largest market. [citation needed] Lupin's estimated annual cost savings to the US health system is approximately $15 ...
DNA Valley (or DNA Alley) [1] is a region in Maryland that serves as a biotechnology hub with a focus on genetic medicine.Roughly traced by Rockville, Frederick, and Baltimore, DNA Valley includes the innovation companies in the Maryland I-270 technology corridor, the various campuses of federal entities such as the FDA and NIH, as well as The University of Maryland, Johns Hopkins University ...
Nearly a week after Lupin Pharmaceuticals announced a voluntary recall of two types of blood pressure medications, the company continues to see its stock price slide (though the hit could have ...
He is the only son of Desh Bandhu Gupta, who founded Lupin in 1968. [3] His eldest sister, Vinita D. Gupta, is the CEO. [citation needed]He has a bachelor's degree in chemical engineering from the University Department of Chemical Technology, Mumbai, and an MBA from the Wharton School, University of Pennsylvania, U.S. in 2002, [3] [1] where he specialized in healthcare, strategic management ...
Desh Bandhu Gupta (8 February 1938 – 26 June 2017) was an Indian billionaire, philanthropist, entrepreneur and the founder of Lupin Limited, a multinational pharmaceutical company. At the time of his death, his net worth was estimated at US$3.6 billion.
The company's first international move took it to Russia in 1992. There, Dr. Reddy's formed a joint venture with the country's biggest pharmaceuticals producer, Biomed.They pulled out in 1995 amid accusations of scandal, involving "a significant material loss due to the activities of Moscow's branch of Reddy's Labs with the help of Biomed's chief executive". [8]
It is requested that an image or photograph of Lupin Limited be included in this article to improve its quality. Please replace this template with a more specific media request template where possible.